View ValuationBonesupport Holding 将来の成長Future 基準チェック /66Bonesupport Holding利益と収益がそれぞれ年間33.8%と23.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に35.9% 45.8%なると予測されています。主要情報33.8%収益成長率45.82%EPS成長率Biotechs 収益成長25.2%収益成長率23.3%将来の株主資本利益率35.93%アナリストカバレッジGood最終更新日22 May 2026今後の成長に関する最新情報お知らせ • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.お知らせ • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).すべての更新を表示Recent updatesお知らせ • Apr 09Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026, at 10:00 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund Swedenお知らせ • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.お知らせ • Oct 23+ 3 more updatesBonesupport Holding AB (publ) to Report Q1, 2026 Results on Apr 22, 2026Bonesupport Holding AB (publ) announced that they will report Q1, 2026 results on Apr 22, 2026お知らせ • Sep 16Bonesuport Announces Positive Results from A Clinical Study Demonstrating Significantly Improved Patient-Based Outcomes for Cerament®? G in Single-Stage Revision Surgery for Patients Patients Lining from Periprosthetic Joint InfectionBonesuport announced positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT®? G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meting, 11-13 September 2025. The prospective clinical study conducted at Charite - Universitatsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS). According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later. The study (CeraHip) is expected to be published during the autumn.お知らせ • Apr 24Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Location: to be held at elite hotel ideon, scheelevagen 27, lund Swedenお知らせ • Apr 01Bonesupport Holding AB (Publ) Files FDA Submission for Cerament VBonesUPPORT announced that the company has submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT® V (vancomycin), with the Food and Drug Administration (FDA), for the indication bone infection. The market approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. The clinical data, from several published studies, demonstrated that CERAMENT G is superior to previous standard options in managing bone infections. With market authorization for CERAMENT V, physicians would be equipped with an additional tool to manage bone infections, primarily caused by Methicillin-Resistant Staphylococcus eg. MRSA or MRSE. CERAMENT V in Europe, where the product has had market approval for several years, represents 15% of the sales of antibiotic-releasing products. Bone grafts with local antibiotic release have proven to be a very important tool in the ambition to drastically reduce the need for systemic antibiotic use and combat antibiotic resistance. CERAMENT V has previously received the categorization of "breakthrough device" for the indication of bone infection from the FDA.お知らせ • Jan 08Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot UlcersBonesupport Holding AB (publ) announced strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, versus 55.1%, p<0.00001].お知らせ • Nov 29Bonesupport Holding AB (publ) Announces Nomination Committee ChangesThe composition of BONESUPPORT's Nomination Committee ahead of the 2025 Annual General Meeting was announced in the company's interim report for the third quarter on October 24 2024. As a result of a subsequent change in ownership, the composition of the Nomination Committee has changed with Anna Sundberg (appointed by Handelsbanken Fonder) leaving the Nomination Committee and Erik Selin (appointed by Erik Selin Fastigheter AB) joining as a new member of the Nomination Committee. Accordingly, the Nomination Committee ahead of the 2025 Annual General Meeting consists of the following members: Caroline Sjösten, appointed by Swedbank Robur Fonder; Erik Selin, appointed by Erik Selin Fastigheter; and Staffan Lindstrand, appointed by HealthCap. In addition, the Chairman of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the Nomination Committee. The Nomination Committee has appointed Caroline Sjösten as Committee chair.お知らせ • Oct 31Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB for SEK 1.3 billion on October 30, 2024. In this transaction, Erik Selin will acquire 3.9 million shares at a rate of SEK 325. Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB on October 30, 2024.お知らせ • Oct 26+ 3 more updatesBonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025Bonesupport Holding AB (publ) announced that they will report Q2, 2025 results on Jul 15, 2025お知らせ • Jun 13+ 1 more updateBonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024Bonesupport Holding AB (publ) announced that Anna Stegmark has been appointed EVP Quality Management & Regulatory Affairs with effect from 1 July 2024. She will also be part of the management team. Anna Stegmark's professional career comprises more than 19 years in the medical device sector, leading global quality and regulatory teams since 2010. Most recently, she was with Radiometer Medical as Director QA Operation.お知らせ • Feb 23Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory AffairsBONESUPPORT AB announced a change in its management team. Kristina Ingvar will leave BONESUPPORT and her role as Executive Vice President Quality Management & Regulatory Affairs (EVP QM&RA). The change is effective as per 22 March 2024. She will take up a position as Corporate Vice President in the global healthcare company Novo Nordisk. Recruitment for the position EVP QM&RA has been initiated.お知らせ • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).お知らせ • Oct 27+ 4 more updatesBonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Bonesupport Holding AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024お知らせ • Oct 17Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone InfectionBONESUPPORTTM announced that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA). The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma.お知らせ • May 26BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open FracturesBONESUPPORT Holding AB announced the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company's antibiotic-eluting bone graft CERAMENT G. The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection. The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%.お知らせ • Oct 30+ 2 more updatesBonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Bonesupport Holding AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023業績と収益の成長予測OTCPK:BOEU.F - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,570727591605612/31/20271,985508389401612/31/20261,48930728029153/31/20261,215185244250N/A12/31/20251,175142216221N/A9/30/20251,119152235241N/A6/30/20251,062148207212N/A3/31/20259981229195N/A12/31/20248991346066N/A9/30/202481491-35N/A6/30/2024735289-29-21N/A3/31/202465626707N/A12/31/2023591245-24-18N/A9/30/2023522214-40-37N/A6/30/2023448-30-66-63N/A3/31/2023382-51-51-48N/A12/31/2022329-68-50-47N/A9/30/2022287-72-62-58N/A6/30/2022257-71-72-68N/A3/31/2022234-82-81-77N/A12/31/2021213-86-87-83N/A9/30/2021205-88-90-88N/A6/30/2021198-96-89-87N/A3/31/2021182-92-88-86N/A12/31/2020181-101-103-100N/A9/30/2020174-115-121-117N/A6/30/2020165-127-143-139N/A3/31/2020166-151-155-150N/A12/31/2019155-161N/A-164N/A9/30/2019132-166N/A-176N/A6/30/2019108-191N/A-189N/A3/31/201998-182N/A-177N/A12/31/201897-176N/A-172N/A9/30/2018101-182N/A-147N/A6/30/2018119-146N/A-128N/A3/31/2018128-132N/A-112N/A12/31/2017129-129N/A-108N/A9/30/2017132-112N/A-112N/A6/30/2017126-124N/A-106N/A3/31/2017114-124N/A-103N/A12/31/2016105-110N/A-82N/A12/31/201562-60N/A-65N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BOEU.Fの予測収益成長率 (年間33.8% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: BOEU.Fの収益 ( 33.8% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。高成長収益: BOEU.Fの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: BOEU.Fの収益 ( 23.3% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: BOEU.Fの収益 ( 23.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BOEU.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 35.9 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 01:09終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bonesupport Holding AB (publ) 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8 アナリスト機関null nullABG Sundal CollierErik CasselDanske BankKristofer Liljeberg-SvenssonDNB Carnegie5 その他のアナリストを表示
お知らせ • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.
お知らせ • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).
お知らせ • Apr 09Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026Bonesupport Holding AB (publ), Annual General Meeting, May 12, 2026, at 10:00 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund Sweden
お知らせ • Jan 14Bonesupport Holding AB (Publ) Provides Earnings Guidance for the Fourth Quarter of 2025 and Full Year 2026Bonesupport Holding AB (publ) provided earnings guidance for the fourth quarter of 2025 and full year 2026. For the quarter, Net sales is expected to total 313 MSEK, representing 36.0% growth at constant exchange rates compared with the same period in 2024. For the year, the company expected sales growth above 35% at constant exchange rates.
お知らせ • Oct 23+ 3 more updatesBonesupport Holding AB (publ) to Report Q1, 2026 Results on Apr 22, 2026Bonesupport Holding AB (publ) announced that they will report Q1, 2026 results on Apr 22, 2026
お知らせ • Sep 16Bonesuport Announces Positive Results from A Clinical Study Demonstrating Significantly Improved Patient-Based Outcomes for Cerament®? G in Single-Stage Revision Surgery for Patients Patients Lining from Periprosthetic Joint InfectionBonesuport announced positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT®? G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meting, 11-13 September 2025. The prospective clinical study conducted at Charite - Universitatsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS). According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later. The study (CeraHip) is expected to be published during the autumn.
お知らせ • Apr 24Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025Bonesupport Holding AB (publ), Annual General Meeting, May 27, 2025, at 10:00 W. Europe Standard Time. Location: to be held at elite hotel ideon, scheelevagen 27, lund Sweden
お知らせ • Apr 01Bonesupport Holding AB (Publ) Files FDA Submission for Cerament VBonesUPPORT announced that the company has submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT® V (vancomycin), with the Food and Drug Administration (FDA), for the indication bone infection. The market approval for CERAMENT® G in 2022 was based on extensive efficacy and patient safety data, with nearly 17,000 clinical data points. The clinical data, from several published studies, demonstrated that CERAMENT G is superior to previous standard options in managing bone infections. With market authorization for CERAMENT V, physicians would be equipped with an additional tool to manage bone infections, primarily caused by Methicillin-Resistant Staphylococcus eg. MRSA or MRSE. CERAMENT V in Europe, where the product has had market approval for several years, represents 15% of the sales of antibiotic-releasing products. Bone grafts with local antibiotic release have proven to be a very important tool in the ambition to drastically reduce the need for systemic antibiotic use and combat antibiotic resistance. CERAMENT V has previously received the categorization of "breakthrough device" for the indication of bone infection from the FDA.
お知らせ • Jan 08Bonesupport Holding AB (publ) Announces Study Results for CERAMENT G and CERAMENT V in Surgical Treatment of Bone Infection Due to Diabetic Foot UlcersBonesupport Holding AB (publ) announced strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, versus 55.1%, p<0.00001].
お知らせ • Nov 29Bonesupport Holding AB (publ) Announces Nomination Committee ChangesThe composition of BONESUPPORT's Nomination Committee ahead of the 2025 Annual General Meeting was announced in the company's interim report for the third quarter on October 24 2024. As a result of a subsequent change in ownership, the composition of the Nomination Committee has changed with Anna Sundberg (appointed by Handelsbanken Fonder) leaving the Nomination Committee and Erik Selin (appointed by Erik Selin Fastigheter AB) joining as a new member of the Nomination Committee. Accordingly, the Nomination Committee ahead of the 2025 Annual General Meeting consists of the following members: Caroline Sjösten, appointed by Swedbank Robur Fonder; Erik Selin, appointed by Erik Selin Fastigheter; and Staffan Lindstrand, appointed by HealthCap. In addition, the Chairman of the Board of BONESUPPORT, Lennart Johansson, is co-opted to the Nomination Committee. The Nomination Committee has appointed Caroline Sjösten as Committee chair.
お知らせ • Oct 31Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB.Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB for SEK 1.3 billion on October 30, 2024. In this transaction, Erik Selin will acquire 3.9 million shares at a rate of SEK 325. Erik Selin acquired 5.92% stake in Bonesupport Holding AB (publ) (OM:BONEX) from Odlander, Fredrikson & Co. AB on October 30, 2024.
お知らせ • Oct 26+ 3 more updatesBonesupport Holding AB (publ) to Report Q2, 2025 Results on Jul 15, 2025Bonesupport Holding AB (publ) announced that they will report Q2, 2025 results on Jul 15, 2025
お知らせ • Jun 13+ 1 more updateBonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024Bonesupport Holding AB (publ) announced that Anna Stegmark has been appointed EVP Quality Management & Regulatory Affairs with effect from 1 July 2024. She will also be part of the management team. Anna Stegmark's professional career comprises more than 19 years in the medical device sector, leading global quality and regulatory teams since 2010. Most recently, she was with Radiometer Medical as Director QA Operation.
お知らせ • Feb 23Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory AffairsBONESUPPORT AB announced a change in its management team. Kristina Ingvar will leave BONESUPPORT and her role as Executive Vice President Quality Management & Regulatory Affairs (EVP QM&RA). The change is effective as per 22 March 2024. She will take up a position as Corporate Vice President in the global healthcare company Novo Nordisk. Recruitment for the position EVP QM&RA has been initiated.
お知らせ • Nov 29Bonesupport Holding AB Provides Sales Guidance for the Year 2024Bonesupport Holding AB provided sales guidance for the year 2024. For the year, the company expects sales growth to be above 40% (in constant currency).
お知らせ • Oct 27+ 4 more updatesBonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Bonesupport Holding AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024
お知らせ • Oct 17Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone InfectionBONESUPPORTTM announced that the company's antibiotic eluting product CERAMENT® V has received categorization as a "breakthrough device" for the indication bone infection by the American Food and Drug Administration (FDA). The categorization breakthrough device is assigned to products that are considered to provide a more effective treatment of severe medical conditions, where there is no comparable equivalent on the market. The categorization has been added to expedite the regulatory review of new medical devices and give patients faster access to new treatment options. CERAMENT® G has previously received breakthrough device designation for the indication's bone infection and trauma.
お知らせ • May 26BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open FracturesBONESUPPORT Holding AB announced the recent publication of long-term follow-up data demonstrating sustained high limb salvage rates and low deep infection rates with the company's antibiotic-eluting bone graft CERAMENT G. The study of 81 patients were managed with a single-stage procedure with CERAMENT G. Patients arrived at hospital with significant tissue loss and exposed bone tissue. With a mean follow-up of 55.8 months after surgery, it was found that 96.3% of patients had avoided an amputation, 96% had achieved bony union within 12 months, and 96.3% had avoided deep infection. The patients from the study were classified as having one of the most severe categories of open fractures (Gustilo-Anderson class IIIB), usually caused by traffic accidents. For this patient population, earlier publications have shown up to 16% amputation rates, non-unions up to 29%, and deep infection rates as high as 52%.
お知らせ • Oct 30+ 2 more updatesBonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023Bonesupport Holding AB (publ) announced that they will report Q3, 2023 results on Oct 26, 2023